Ernexa Therapeutics (ERNAW) Other Non-Current Liabilities (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Other Non-Current Liabilities of $1000.0 for Q1 2026, down 99.1% on a YoY basis from $111000.0 in Q1 2025, and down 97.67% quarter-over-quarter from $43000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Other Non-Current Liabilities for 17 years, with the latest figure at $1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 99.1% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $1000.0 (down 99.1% YoY), and the FY2025 full-year result was $43000.0, up 4200.0% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1000.0, down from $43000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $13.3 million in Q1 2022, with the low at $1000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $1.1 million across 5 years, with a median of $112000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 58138.2% — and 2026, when it sank 99.1%.
- Ernexa Therapeutics' Other Non-Current Liabilities stood at $331000.0 in 2022, then slumped by 74.62% to $84000.0 in 2023, then slumped by 98.81% to $1000.0 in 2024, then surged by 4200.0% to $43000.0 in 2025, then tumbled by 97.67% to $1000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $1000.0 (Q1 2026), $43000.0 (Q4 2025), and $112000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 111,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | 186,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Mar 31, 2023 | 376,000.00 |
| Dec 31, 2022 | 331,000.00 |
| Sep 30, 2022 | 1.69 Mn |
| Jun 30, 2022 | 2.52 Mn |
| Mar 31, 2022 | 13.32 Mn |
| Sep 30, 2021 | 22,863.00 |
| Jun 30, 2021 | 19.29 Mn |
| Mar 31, 2021 | 22,863.00 |